Want to join the conversation?
$EW now sees 2016 sales to be at high end of its prior $2.7-3Bil range based on strong 1H results, expected 3Q approval of intermediate risk in the U.S., and momentum of therapy adoption globally. $EW raised FY16 adjusted EPS outlook to $2.78-2.88 from prior range of $2.67-2.77. For 3Q16, $EW sees sales of $720-760MM and adjusted EPS of $0.62-0.68.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?